Literature DB >> 16205437

Botulinum toxin type a in the treatment of children with congenital muscular torticollis.

Joyce L Oleszek1, Nicki Chang, Susan D Apkon, Pamela E Wilson.   

Abstract

This is a retrospective case series describing the use of botulinum toxin type A in the treatment of children with congenital muscular torticollis who fail to progress with conservative management. A total of 27 children with congenital muscular torticollis, 6-18 mos of age, received 30 botulinum toxin type A injections into their sternocleidomastoid or upper trapezius muscle, or both, at a pediatric tertiary care center between 1995 and 2001. Three children received repeat injections. Twenty of 27 children (74%) had improved cervical rotation or head tilt after the injections, and 2 of 27 (7%) experienced transient adverse events, specifically, mild dysphagia and neck weakness. This series suggests that botulinum toxin type A may be a safe and effective treatment option for children with congenital muscular torticollis who are unresponsive to a traditional regimen of physical therapy and a home program. A prospective, randomized controlled trial is necessary to definitively assess the role of botulinum toxin type A in this population.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16205437     DOI: 10.1097/01.phm.0000179516.45373.c4

Source DB:  PubMed          Journal:  Am J Phys Med Rehabil        ISSN: 0894-9115            Impact factor:   2.159


  9 in total

1.  The effective zone of botulinum toxin A injections in the sternocleidomastoid muscle.

Authors:  J H Lee; B N Lee; Seung-Ho Han; X C An; R H Chung
Journal:  Surg Radiol Anat       Date:  2010-10-01       Impact factor: 1.246

2.  The thickness of the sternocleidomastoid muscle as a prognostic factor for congenital muscular torticollis.

Authors:  Jae Deok Han; Seung Hwan Kim; Seung Jae Lee; Myong Chul Park; Shin-Young Yim
Journal:  Ann Rehabil Med       Date:  2011-06-30

3.  Support Vector Regression-based Model to Analyze Prognosis of Infants with Congenital Muscular Torticollis.

Authors:  Suk-Tae Seo; In-Hee Lee; Chang-Sik Son; Hee-Joon Park; Hyoung-Seob Park; Hyuck-Jun Yoon; Yoon-Nyun Kim
Journal:  Healthc Inform Res       Date:  2010-12-31

4.  Effectiveness and safety of botulinum toxin type a in children with musculoskeletal conditions: what is the current state of evidence?

Authors:  Noémi Dahan-Oliel; Bahar Kasaai; Kathleen Montpetit; Reggie Hamdy
Journal:  Int J Pediatr       Date:  2012-04-05

5.  A comparison of outcomes of asymmetry in infants with congenital muscular torticollis according to age upon starting treatment.

Authors:  KyeongSoo Lee; EunJung Chung; Byoung-Hee Lee
Journal:  J Phys Ther Sci       Date:  2017-03-22

6.  Correlations between the Clinical and Ultrasonographic Parameters of Congenital Muscular Torticollis without a Sternocleidomastoid Mass.

Authors:  Jisun Hwang; Eun Kyung Khil; Soo Jin Jung; Jung Ah Choi
Journal:  Korean J Radiol       Date:  2020-07-27       Impact factor: 3.500

7.  Intramuscular injection of Botox causes tendon atrophy by induction of senescence of tendon-derived stem cells.

Authors:  Peilin Chen; Ziming Chen; Christopher Mitchell; Junjie Gao; Lianzhi Chen; Allan Wang; Toby Leys; Euphemie Landao-Bassonga; Qiujian Zheng; Tao Wang; Minghao Zheng
Journal:  Stem Cell Res Ther       Date:  2021-01-07       Impact factor: 6.832

8.  Sternocleidomastoid size and upper trapezius muscle thickness in congenital torticollis patients: A retrospective observational study.

Authors:  Dong Rak Kwon; Yoontae Kim
Journal:  Medicine (Baltimore)       Date:  2021-12-30       Impact factor: 1.889

9.  Congenital muscular torticollis: the reliability of visual estimation in the assessment of cervical spine active rotation and head tilt by physiotherapists and the impact of clinical experience.

Authors:  Anthea Seager; Dara Meldrum; Ronan Conroy; Helen P French
Journal:  Eur J Pediatr       Date:  2020-05-29       Impact factor: 3.183

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.